Biontech Se

Abbott Gmbh & Co Kg

Abbvie Deutschland Gmbh and Co Kg

Bointech Se

Christophe Henry

Liliane Unger

Andreas Haupt

Wilfried Martin Braje

Karla Drescher

Sean Colm Turner

Roland Grandel

Wilfried Lubisch

Gisela Backfisch

Armin Beyerbach

The invention relates to imidazoquinoline derivatives and to pharmaceutical compositions containing the imidazoquinoline derivatives. The imidazoquinoline derivatives of the invention are useful as toll-like receptor agonists, in particular agonists of TLR7, and promote induction of certain cytokines.

Substituted imidazoquinolines

Substituted imidazoquinolines as agonists of TLR7

The invention relates to imidazoquinoline derivatives and to pharmaceutical compositions containing the imidazoquinoline derivatives. The imidazoquinoline derivatives of the invention are useful as toll-like receptor agonists, in particular agonists of TLR7, and promote induction of certain cytokines. 

The present invention relates to aromatic compounds of the formula I wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical Rand wherein Ar may also carry 1 or 2 radicals R; The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor

The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CHor CHR; Ris H, C,-C-alkyl, C,-C-alkyl substituted by C-C-cycloalkyl, C-C-hydroxyalkyl, fluorinated C,-C-alkyl, C-C-cycloalkyl, fluorinated C-C-cycloalkyl, C-Calkenyl, fluorinated C-C-alkenyl, formyl, acetyl or propionyl; R, Rand Rare, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one or more substituents selected from halogen, methyl, methoxy and CF; E is NRor CH, wherein Ris H or C-C-alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR, where Ris H, C-C-alkyl, fluorinated C-C-alkyl, C-Calkylcarbonyl or fluorinated C-C-alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R, wherein the variable Rhas the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand. 

Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor

The invention relates to compounds of the formula (I). The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

Growing community of inventors

Munich, Germany

Christophe Henry